Symbols

LNAI

Lunai·NASDAQ

--(--)

Market Open: --

--(--)

Pre-Market: --

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About LNAI

Lunai Bioworks Inc.

A data-driven biotech company leveraging artificial intelligence to integrate multi-dimensional biological data for developing diagnostic and therapeutic solutions for diseases such as Alzheimer's

Industry

Biological Technology

Established Date

01/18/2011

Listing Date

12/10/2018

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

06-30

Website

www.renovarogroup.com

Security Type

Common stock

Office address

2080 Century Park East, Suite 906, Los Angeles, CA 90067

Business

Introduction

Lunai Bioworks Inc., incorporated in Delaware on January 18, 2011, operates through three subsidiaries: Renovaro Biosciences, Renovaro Cube and BioSymetrics. Renovaro Cube, including GediCube Intl. Ltd., and its subsidiaries, were acquired on February 13, 2024, and BioSymetrics and its subsidiaries were acquired on April 8, 2025. Renovaro Biosciences, the company's biotechnology division, focuses on the development of allogeneic cell and gene therapies designed to strengthen the immune response and designed to support long-term cancer remission. Following the acquisition of GediCube INTL., Lunai has increasingly emphasized molecular diagnostic and oncology technologies. The company's development areas include innovative therapeutic vaccination platforms for solid tumors such as pancreatic cancer, liver cancer, triple-negative breast cancer, and head and neck cancer. Its approach utilizes engineered donor cells and molecular diagnostic techniques that have the potential to provide "off-the-shelf" treatment options that reduce the delay between diagnosis and treatment.

Company Financials

EPS

LNAI has released its 2024 Q2 earnings. EPS was reported at -0.07, versus the expected 0, missing expectations. The chart below visualizes how LNAI has performed over recent quarters, highlighting trends in earnings surprises.